2-AMINO-6-METHYL-4,4A,5,6-TETRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL-1,3-THIAZOL-4-YL AMIDES

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (l), (see formula I) wherein the variable R1 is as defined in the specification. Corresponding pharmaceutical comp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHANG, LEI, BECK, ELIZABETH MARY, O'NEILL, BRIAN THOMAS, BARREIRO, GABRIELA, LACHAPELLE, ERIK ALPHIE, BUTLER, CHRISTOPHER RYAN, BRODNEY, MICHAEL AARON, ROGERS, BRUCE NELSEN
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (l), (see formula I) wherein the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of use as a BACE1 inhibitor, and which compounds may also be used in the treatment of Alzheimer's disease or Type 2 diabetes, methods of synthesis, and intermediates are also disclosed. L'invention concerne des composés, des tautomères et des sels pharmaceutiquement acceptables des composés divulgués, les composés présentant la structure de formule (I), et la variable R1 étant telle que définie dans la description. L'invention concerne également des compositions pharmaceutiques, des méthodes de traitement, des procédés de synthèse et des produits intermédiaires correspondants.